Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex
Identifieur interne : 004027 ( Main/Exploration ); précédent : 004026; suivant : 004028Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex
Auteurs : F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; J. C. Martel [Canada] ; M. F. Piercey [États-Unis] ; P. J. Be Dard [Canada] ; T. Di Paolo [Canada]Source :
- Brain Research [ 0006-8993 ] ; 1995.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Agonist, Akinesia, Aminoquinolines (adverse effects), Animal, Animals, Autoradiography, Basal ganglia, Chemotherapy, Corpus Striatum (metabolism), Corpus striatum, D2 Dopamine receptor, Dopa, Dopamine, Dopamine Agonists (adverse effects), Dopamine receptor, Dyskinesia, Dyskinesia, Drug-Induced (metabolism), Female, GABAA receptor, Gabaergic receptor A, Globus Pallidus, Globus Pallidus (metabolism), Imidazoles (adverse effects), Levodopa (adverse effects), Macaca fascicularis, Monkey, Pallidum, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (metabolism), Parkinson disease, Parkinson's disease, Receptors, Dopamine D1 (metabolism), Receptors, Dopamine D2 (metabolism), Receptors, GABA (metabolism), Toxicity, Treatment.
- MESH :
- chemical , adverse effects : Aminoquinolines, Dopamine Agonists, Imidazoles, Levodopa.
- chemical , metabolism : Receptors, Dopamine D1, Receptors, Dopamine D2, Receptors, GABA.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- metabolism : Corpus Striatum, Dyskinesia, Drug-Induced, Globus Pallidus, Parkinson Disease, Secondary.
- Animals, Autoradiography, Female, Macaca fascicularis.
Abstract
Abstract: Dopamine D1 and D2 receptors as well as the GABA/benzodiazepine receptor complex in the striatum and the globus pallidus (internal: GPi and external: GPe) were studied by autoradiography using [3H]SCH 23390, [3H]spiperone, and [3H]flunitrazepam ([3H]FNZ) respectively, in five groups of cynomolgus monkeys. These included (i) untreated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-monkeys; (ii) MPTP monkeys treated chronically with levodopa injections; (iii) MPTP monkeys treated chronically with injections of the novel D2 agonist U91356A; (iv) MPTP monkeys treated chronically with U91356A delivered through an osmotic mini-pump; and (5) naive controls. Animals treated in a pulsatile mode with U91356A or levodopa injections showed progressive sensitization to their respective drug and developed choreic dyskinesia. In contrast, animals treated in a continuous mode with U91356A showed behavioral tolerance but did not develop dyskinesia. A trend for a down-regulation of putaminal D2 receptors was observed following D2 agonist stimulation with U913356A. Striatal [3H]FNZ binding was significantly decreased only in animals treated in a continuous mode with U91356A. The dopamine receptor decrease in the striatum could be implicated with the development of tolerance but cannot explain the appearnce of dyskinesia. Denervation by MPTP was associated with a decrease of the GPe/GPi [3H]FNZ binding ratio which reflects an imbalance of striatal output pathways; this ratio was not reversed by any of the treatments although changes were observed in the GPe and GPi. Indeed, pulsatile U91356A treatment restored the decreased [3H]FNZ binding in the GPe near control values and levodopa showed a similar tendency. A significant increase of [3H]FNZ binding in the GPi only of dyskinetic monkeys, namely those treated with pulsatile U91356A or levodopa was seen compared to untreated MPTP or naive controls. This GABAA receptor up-regulation might lead to a supersensitive state of the GPi to gabaergic input which may be involved in the mechanism underlying the development of dopaminomimetic-induced dyskinesia.
Url:
DOI: 10.1016/0006-8993(95)00229-J
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001183
- to stream Istex, to step Curation: 001183
- to stream Istex, to step Checkpoint: 001A01
- to stream Main, to step Merge: 004749
- to stream PascalFrancis, to step Corpus: 000F67
- to stream PascalFrancis, to step Curation: 000F56
- to stream PascalFrancis, to step Checkpoint: 000E58
- to stream Main, to step Merge: 004815
- to stream PubMed, to step Corpus: 001919
- to stream PubMed, to step Curation: 001919
- to stream PubMed, to step Checkpoint: 001919
- to stream Ncbi, to step Merge: 002397
- to stream Ncbi, to step Curation: 002397
- to stream Ncbi, to step Checkpoint: 002397
- to stream Main, to step Merge: 004625
- to stream Main, to step Curation: 004027
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex</title><author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name></author><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></author><author><name sortKey="Martel, J C" sort="Martel, J C" uniqKey="Martel J" first="J. C." last="Martel">J. C. Martel</name></author><author><name sortKey="Piercey, M F" sort="Piercey, M F" uniqKey="Piercey M" first="M. F." last="Piercey">M. F. Piercey</name></author><author><name sortKey="Be Dard, P J" sort="Be Dard, P J" uniqKey="Be Dard P" first="P. J." last="Be Dard">P. J. Be Dard</name></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B8E5EA45A08380B44917EE3FC236DE60062DDA44</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0006-8993(95)00229-J</idno><idno type="url">https://api-v5.istex.fr/document/B8E5EA45A08380B44917EE3FC236DE60062DDA44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001183</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001183</idno><idno type="wicri:Area/Istex/Curation">001183</idno><idno type="wicri:Area/Istex/Checkpoint">001A01</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A01</idno><idno type="wicri:doubleKey">0006-8993:1995:Calon F:levodopa:or:d</idno><idno type="wicri:Area/Main/Merge">004749</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:95-0359227</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F67</idno><idno type="wicri:Area/PascalFrancis/Curation">000F56</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000E58</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000E58</idno><idno type="wicri:doubleKey">0006-8993:1995:Calon F:levodopa:or:d</idno><idno type="wicri:Area/Main/Merge">004815</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:7663983</idno><idno type="wicri:Area/PubMed/Corpus">001919</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001919</idno><idno type="wicri:Area/PubMed/Curation">001919</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001919</idno><idno type="wicri:Area/PubMed/Checkpoint">001919</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001919</idno><idno type="wicri:Area/Ncbi/Merge">002397</idno><idno type="wicri:Area/Ncbi/Curation">002397</idno><idno type="wicri:Area/Ncbi/Checkpoint">002397</idno><idno type="wicri:doubleKey">0006-8993:1995:Calon F:levodopa:or:d</idno><idno type="wicri:Area/Main/Merge">004625</idno><idno type="wicri:Area/Main/Curation">004027</idno><idno type="wicri:Area/Main/Exploration">004027</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex</title><author><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Centre de recherche en endocrinologie mole´culaire, Le Centre Hospitalier de l'Universite´Laval, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author><author><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Centre de recherche en endocrinologie mole´culaire, Le Centre Hospitalier de l'Universite´Laval, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Center, Hoˆpital de l'Enfant-Je´sus, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author><author><name sortKey="Martel, J C" sort="Martel, J C" uniqKey="Martel J" first="J. C." last="Martel">J. C. Martel</name><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Centre de recherche en endocrinologie mole´culaire, Le Centre Hospitalier de l'Universite´Laval, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Center, Hoˆpital de l'Enfant-Je´sus, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author><author><name sortKey="Piercey, M F" sort="Piercey, M F" uniqKey="Piercey M" first="M. F." last="Piercey">M. F. Piercey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>CNS Research Division, The Upjohn Co., Kalamazoo, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Be Dard, P J" sort="Be Dard, P J" uniqKey="Be Dard P" first="P. J." last="Be Dard">P. J. Be Dard</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, Faculty of Medicine, Laval University and Neurobiology Research Center, Hoˆpital de l'Enfant-Je´sus, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author><author><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><affiliation></affiliation><affiliation wicri:level="1"><country>Canada</country><wicri:regionArea>School of Pharmacy, Laval University and Centre de recherche en endocrinologie mole´culaire, Le Centre Hospitalier de l'Universite´Laval, Que´bec</wicri:regionArea><wicri:noRegion>Que´bec</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain Research</title><title level="j" type="abbrev">BRES</title><idno type="ISSN">0006-8993</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">680</biblScope><biblScope unit="issue">1–2</biblScope><biblScope unit="page" from="43">43</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0006-8993</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8993</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Agonist</term><term>Akinesia</term><term>Aminoquinolines (adverse effects)</term><term>Animal</term><term>Animals</term><term>Autoradiography</term><term>Basal ganglia</term><term>Chemotherapy</term><term>Corpus Striatum (metabolism)</term><term>Corpus striatum</term><term>D2 Dopamine receptor</term><term>Dopa</term><term>Dopamine</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine receptor</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (metabolism)</term><term>Female</term><term>GABAA receptor</term><term>Gabaergic receptor A</term><term>Globus Pallidus</term><term>Globus Pallidus (metabolism)</term><term>Imidazoles (adverse effects)</term><term>Levodopa (adverse effects)</term><term>Macaca fascicularis</term><term>Monkey</term><term>Pallidum</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (metabolism)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Receptors, Dopamine D1 (metabolism)</term><term>Receptors, Dopamine D2 (metabolism)</term><term>Receptors, GABA (metabolism)</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Aminoquinolines</term><term>Dopamine Agonists</term><term>Imidazoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term><term>Receptors, GABA</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dyskinesia, Drug-Induced</term><term>Globus Pallidus</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Autoradiography</term><term>Female</term><term>Macaca fascicularis</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Akinésie</term><term>Animal</term><term>Chimiothérapie</term><term>Corps strié</term><term>Dopa</term><term>Dopamine</term><term>Pallidum</term><term>Parkinson maladie</term><term>Récepteur dopaminergique D2</term><term>Récepteur gabaergique A</term><term>Singe</term><term>Toxicité</term><term>Traitement</term><term>U 91356A</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Dopamine D1 and D2 receptors as well as the GABA/benzodiazepine receptor complex in the striatum and the globus pallidus (internal: GPi and external: GPe) were studied by autoradiography using [3H]SCH 23390, [3H]spiperone, and [3H]flunitrazepam ([3H]FNZ) respectively, in five groups of cynomolgus monkeys. These included (i) untreated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-monkeys; (ii) MPTP monkeys treated chronically with levodopa injections; (iii) MPTP monkeys treated chronically with injections of the novel D2 agonist U91356A; (iv) MPTP monkeys treated chronically with U91356A delivered through an osmotic mini-pump; and (5) naive controls. Animals treated in a pulsatile mode with U91356A or levodopa injections showed progressive sensitization to their respective drug and developed choreic dyskinesia. In contrast, animals treated in a continuous mode with U91356A showed behavioral tolerance but did not develop dyskinesia. A trend for a down-regulation of putaminal D2 receptors was observed following D2 agonist stimulation with U913356A. Striatal [3H]FNZ binding was significantly decreased only in animals treated in a continuous mode with U91356A. The dopamine receptor decrease in the striatum could be implicated with the development of tolerance but cannot explain the appearnce of dyskinesia. Denervation by MPTP was associated with a decrease of the GPe/GPi [3H]FNZ binding ratio which reflects an imbalance of striatal output pathways; this ratio was not reversed by any of the treatments although changes were observed in the GPe and GPi. Indeed, pulsatile U91356A treatment restored the decreased [3H]FNZ binding in the GPe near control values and levodopa showed a similar tendency. A significant increase of [3H]FNZ binding in the GPi only of dyskinetic monkeys, namely those treated with pulsatile U91356A or levodopa was seen compared to untreated MPTP or naive controls. This GABAA receptor up-regulation might lead to a supersensitive state of the GPi to gabaergic input which may be involved in the mechanism underlying the development of dopaminomimetic-induced dyskinesia.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Calon, F" sort="Calon, F" uniqKey="Calon F" first="F." last="Calon">F. Calon</name></noRegion><name sortKey="Be Dard, P J" sort="Be Dard, P J" uniqKey="Be Dard P" first="P. J." last="Be Dard">P. J. Be Dard</name><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><name sortKey="Di Paolo, T" sort="Di Paolo, T" uniqKey="Di Paolo T" first="T." last="Di Paolo">T. Di Paolo</name><name sortKey="Goulet, M" sort="Goulet, M" uniqKey="Goulet M" first="M." last="Goulet">M. Goulet</name><name sortKey="Martel, J C" sort="Martel, J C" uniqKey="Martel J" first="J. C." last="Martel">J. C. Martel</name><name sortKey="Martel, J C" sort="Martel, J C" uniqKey="Martel J" first="J. C." last="Martel">J. C. Martel</name></country><country name="États-Unis"><region name="Michigan"><name sortKey="Piercey, M F" sort="Piercey, M F" uniqKey="Piercey M" first="M. F." last="Piercey">M. F. Piercey</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004027 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004027 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B8E5EA45A08380B44917EE3FC236DE60062DDA44
|texte= Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex
}}
| This area was generated with Dilib version V0.6.29. |  |